S&P 500   4,158.24
DOW   33,212.96
QQQ   309.10
S&P 500   4,158.24
DOW   33,212.96
QQQ   309.10
S&P 500   4,158.24
DOW   33,212.96
QQQ   309.10
S&P 500   4,158.24
DOW   33,212.96
QQQ   309.10

Sonoma Pharmaceuticals (SNOA) Stock Forecast, Price & News

+0.05 (+1.51%)
(As of 05/27/2022 12:00 AM ET)
Today's Range
50-Day Range
52-Week Range
15,076 shs
Average Volume
728,174 shs
Market Capitalization
$10.44 million
P/E Ratio
Dividend Yield
30 days | 90 days | 365 days | Advanced Chart
Receive SNOA News and Ratings via Email

Sign-up to receive the latest news and ratings for Sonoma Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

Sonoma Pharmaceuticals logo

About Sonoma Pharmaceuticals

Sonoma Pharmaceuticals, Inc., develops and produces stabilized hypochlorous acid (HOCl) products for various applications, including wound care, animal health care, eye care, oral care, and dermatological conditions in the United States and internationally. The company offers Epicyn, an antimicrobial facial cleanser; Levicyn, an HOCl based prescription product to manage and relieve burning, itching, and pain experienced with various types of dermatoses; Celacyn gel, a product indicated to promote healing through the management of new and old scars; and SebuDerm to manage and relieve the burning, itching, pain, and distraction associated with seborrhea and seborrheic dermatitis. It also provides Acuicyn, a HOCl-based product indicated to relieve itch and inflammation while helping to keep areas around the eye clean; and Microcyn, a line of products to stimulate expedited healing by targeting various pathogens, as well as antibiotic-resistant strains that slow natural healing of wounds. In addition, the company offers MicrocynAH, an HOCl-based solution designed to relieve common symptoms of hot spots, scratches, skin rashes post-surgical sites, and irritated animal skin for healing; Microdacyn60 oral care solution for the treatment of mouth and throat infections; Lasercyn gel intended for the management of minor skin irritations; MucoClyns for the use in emergencies and safe to use on mucous membranes, cuts, abrasions, burns, and body surfaces; Endocyn root canal irrigation solutions; Pediacyn atopic dermatitis hydrogel; Gramaderm for the treatment of topical mild to moderate acne; Microsafe, a surface disinfectant; and Sinudox for nasal irrigation, including moistening of cuts, abrasions, and lacerations located in the nasal cavity. The company was formerly known as Oculus Innovative Sciences, Inc. and changed its name to Sonoma Pharmaceuticals, Inc. in December 2016. Sonoma Pharmaceuticals, Inc. was incorporated in 1999 and is based in Woodstock, Georgia.


See More Headlines

Industry, Sector and Symbol

Pharmaceutical preparations
Current Symbol
Year Founded

Sales & Book Value

Annual Sales
$18.63 million
Book Value
$2.58 per share


Net Income
$-3.95 million
Pretax Margin




Free Float
Market Cap
$10.44 million
Not Optionable

Company Calendar

Last Earnings
Next Earnings (Estimated)
Fiscal Year End

Social Links


Overall MarketRank

0.91 out of 5 stars

Medical Sector

1282nd out of 1,424 stocks

Pharmaceutical Preparations Industry

629th out of 681 stocks

Analyst Opinion: 0.0Community Rank: 4.5Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -

Sonoma Pharmaceuticals (NASDAQ:SNOA) Frequently Asked Questions

Are investors shorting Sonoma Pharmaceuticals?

Sonoma Pharmaceuticals saw a increase in short interest in May. As of May 15th, there was short interest totaling 185,500 shares, an increase of 138.4% from the April 30th total of 77,800 shares. Based on an average daily volume of 1,120,000 shares, the short-interest ratio is presently 0.2 days.
View Sonoma Pharmaceuticals' Short Interest

When is Sonoma Pharmaceuticals' next earnings date?

Sonoma Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Wednesday, July 13th 2022.
View our earnings forecast for Sonoma Pharmaceuticals

How were Sonoma Pharmaceuticals' earnings last quarter?

Sonoma Pharmaceuticals, Inc. (NASDAQ:SNOA) released its quarterly earnings data on Thursday, November, 14th. The company reported ($0.91) EPS for the quarter, topping analysts' consensus estimates of ($1.18) by $0.27. The company had revenue of $4.97 million for the quarter. Sonoma Pharmaceuticals had a negative net margin of 46.46% and a negative trailing twelve-month return on equity of 68.36%.
View Sonoma Pharmaceuticals' earnings history

Who are Sonoma Pharmaceuticals' key executives?
Sonoma Pharmaceuticals' management team includes the following people:
  • Ms. Amy M. Trombly, CEO & Pres (Age 54, Pay $428k)
  • Mr. Jerome Dvonch, Chief Financial Officer (Age 53, Pay $221.91k)
  • Mr. Bruce Thornton, COO & Corp. Sec. (Age 58, Pay $365k)
  • Dr. Robert Northey, Exec. VP of R&D (Age 65)
  • Ms. Victoria Covel, Assistant Controller
What other stocks do shareholders of Sonoma Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Sonoma Pharmaceuticals investors own include Inovio Pharmaceuticals (INO), VelocityShares Daily 2x VIX Short-Term ETN (TVIX), Sorrento Therapeutics (SRNE), Bristol-Myers Squibb (BMY), Gilead Sciences (GILD), Amarin (AMRN), Pfizer (PFE), Nabriva Therapeutics (NBRV), Verastem (VSTM) and Vaxart (VXRT).

What is Sonoma Pharmaceuticals' stock symbol?

Sonoma Pharmaceuticals trades on the NASDAQ under the ticker symbol "SNOA."

Who are Sonoma Pharmaceuticals' major shareholders?

Sonoma Pharmaceuticals' stock is owned by a number of retail and institutional investors. Top institutional investors include Vanguard Group Inc. (0.89%).
View institutional ownership trends for Sonoma Pharmaceuticals

Which institutional investors are selling Sonoma Pharmaceuticals stock?

SNOA stock was sold by a variety of institutional investors in the last quarter, including Vanguard Group Inc..
View insider buying and selling activity for Sonoma Pharmaceuticals
or view top insider-selling stocks.

How do I buy shares of Sonoma Pharmaceuticals?

Shares of SNOA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Sonoma Pharmaceuticals' stock price today?

One share of SNOA stock can currently be purchased for approximately $3.37.

How much money does Sonoma Pharmaceuticals make?

Sonoma Pharmaceuticals has a market capitalization of $10.44 million and generates $18.63 million in revenue each year. The company earns $-3.95 million in net income (profit) each year or ($2.630010) on an earnings per share basis.

How many employees does Sonoma Pharmaceuticals have?

Sonoma Pharmaceuticals employs 14 workers across the globe.

When was Sonoma Pharmaceuticals founded?

Sonoma Pharmaceuticals was founded in 1999.

What is Sonoma Pharmaceuticals' official website?

The official website for Sonoma Pharmaceuticals is www.sonomapharma.com.

How can I contact Sonoma Pharmaceuticals?

Sonoma Pharmaceuticals' mailing address is 645 MOLLY LANE SUITE 150, WOODSTOCK GA, 30189. The company can be reached via phone at (800) 759-9305, via email at [email protected], or via fax at 707-283-0551.

This page was last updated on 5/28/2022 by MarketBeat.com Staff


Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.